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Endothelial dysregulation is central to the pathogenesis of
acute Plasmodium falciparum infection. It has been assumed
that this dysregulation resolves rapidly after treatment, but
this return to normality has been neither demonstrated nor
quantiﬁed. We therefore measured a panel of plasma endo-
thelial markers acutely and in convalescence in Malawian
children with uncomplicated or cerebral malaria. Evidence
of persistent endothelial activation and inﬂammation, indi-
cated by increased plasma levels of soluble intracellular adhe-
sion molecule 1, angiopoetin 2, and C-reactive protein, were
observed at 1 month follow-up visits. These vascular changes
may represent a previously unrecognized contributor to
ongoing malaria-associated morbidity and mortality.
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Plasmodium falciparum causes approximately 300 million clin-
ical episodes of malaria every year, mainly in sub–Saharan
Africa [1]. In hyperendemic regions, children may receive >1
infective bite per day and experience repeated clinical episodes
[2]. Although acute infection is directly responsible for 750 000
deaths [3], it is increasingly apparent that there is an additional
indirect burden of mortality. Several studies have shown that
reducing malaria transmission in a population may be followed
by all-cause childhood mortality reductions as high as 70%, a
greater effect on mortality than can be attributed to reducing
parasitemic febrile illness alone [2, 4, 5]. The cause of this addi-
tional burden remains uncertain. Given the alteration in vascu-
lar endothelial function during acute malaria pathogenesis, 1
plausible mechanism is that endothelial dysfunction persists
beyond the acute febrile episode and inﬂuences the risk or
outcome of reinfection or other diseases.
We postulated that malaria infection induces persistent alter-
ation in endothelial activation. We tested this using a panel of
plasma endothelial markers linked to key endothelial functions:
soluble ICAM-1 (sICAM-1) and sE-selectin for endothelial ac-
tivation; angiopoetin 2 (Ang2) for angiogenesis and endothelial
quiescence; C-reactive protein (CRP) for inﬂammation; pro-
thrombin fragment F1 + 2 for a procoagulant state; and soluble
thrombomodulin (sTM) for endothelial damage.
METHODS
Recruitment took place at the Queen Elizabeth Central Hospi-
tal, Blantyre, Malawi between January 2010 and June 2011.
Children aged 1–12 years were recruited into 1 of 4 clinical cat-
egories: (1) cerebral malaria (CM) cases, who fulﬁlled World
Health Organization (WHO) diagnostic criteria [6] and had at
least 1 feature of malarial retinopathy [7]; (2) children with un-
complicated malaria (UM); (3) children with aparasitemic mild
febrile illness (MF); and (4) aparasitemic healthy controls
(HC), recruited from well children attending elective surgery.
Children were included in the UM and MF groups if they had
an axillary temperature >37.5°C and no features of organ com-
promise as indicated by WHO criteria [6]. Parasitemia was
screened for on admission and in follow-up visits using a com-
bined P. falciparum histidine rich protein and pan-malarial
lactate dehydrogenase rapid diagnostic test kit, and in patients
in whom both parameters were positive, parasitemia was con-
ﬁrmed on blood smear. In all patient groups, children were
excluded if they had evidence of meningitis or severe malnutri-
tion, had WHO stage 4 human immunodeﬁciency virus infec-
tion, or were on antiretroviral therapy. Informed consent was
given by the parent or legal guardian of all children enrolled in
the study. The study was approved by the College of Medicine
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Research Ethics Committee in Malawi (No. P.02/10/860) and
by the Liverpool School of Tropical Medicine ethical board in
the United Kingdom (No. 09.74).
CM patients were managed on a pediatric high-dependency
unit according to established protocols. They were treated with
intravenous quinine for a minimum of 3 doses, until either 2
consecutive negative malaria blood ﬁlms or until they could tol-
erate oral medication. They were then given a 3-day course of
oral lumefantrine-artemether according to national treatment
guidelines. UM patients were treated with a 3-day course of
oral lumefantrine-artemether, and MF patients were given
treatment as deemed clinically appropriate by the local clinical
team. Patients were excluded from further analysis if they had
fever or were parasitemic on the day of follow-up.
Citrated plasma samples were taken at presentation and at 1
week and 1 month follow-up visits, and plasma was stored at
−80°C until required. sICAM-1, sE-Selectin, sTM, CRP, and
Ang2 concentrationswere determinedusing commercial enzyme-
-linked immunosorbent assay kits and F1 + 2 using the Enzyg-
nost F1 + 2 micro kit.
Statistical analysis was performed using Stata version 11 and
Prism version 5.0 software. Skewed data were log-transformed,
and differences between groups were compared by 1-way analy-
sis of variance, with the Tukey honestly signiﬁcant difference
test to adjust for multiple comparisons. All tests were 2-tailed,
and signiﬁcance was set at the 5% level.
RESULTS
Eighty-eight children with MF, 84 children with UM, 18 chil-
dren with CM, and 36 HC children were recruited (see
Table 1). Approximately 50% of these were followed-up to day
28 (Supplementary Figure 1).
At enrollment (day 0), sICAM-1, Ang2, CRP, and sE-selectin
concentrations were signiﬁcantly higher in all febrile groups
when compared with the HC group; sTM was raised in UM
and CM patients, and F1 + 2 was raised in CM patients
(Table 1, Figure 1, and Supplementary Figure 2). At 7 days
postenrollment, CRP and Ang2 remained signiﬁcantly raised in
all groups when compared with the HC group. ICAM-1 re-
mained raised in UM and CM patients and E-selectin, and
F1 + 2 remained raised in CM patients only. At 28 days posten-
rollment, ICAM-1 and Ang2 remained signiﬁcantly raised in
MF and UM patients. CRP was signiﬁcantly raised in CM pa-
tients only.
DISCUSSION
The endothelial lining of blood vessels has a critical role in the
regulation of blood ﬂow, permeability, coagulation, inﬂamma-
tion, and innate and adaptive immunity [8]. A key determinant
of endothelial function is the repertoire of surface receptors ex-
pressed, and these phenotypes are highly speciﬁc for the vascu-
lar beds of different organs [8]. Disruption of this surface
receptor phenotype is critical in the pathogenesis of many dis-
eases, including bacterial sepsis, cardiovascular disease, inﬂam-
matory bowel disease, and malaria [9, 10]. In acute P.
falciparum malaria, cytokine- and parasite-mediated alteration
of endothelial phenotype leads to endothelial dysfunction and a
procoagulant state [10, 11]. In turn, the upregulation of several
inducible endothelial surface receptors, including E-selectin
and ICAM-1, facilitates the cytoadherence of P. falciparum–in-
fected red blood cells (iRBCs) [10], a key component of the
pathogenesis of CM [12]. It has been assumed that after each
infection following iRBC elimination these perturbations
resolve quickly and completely, with the endothelium rapidly
returning to its predisease state. Here we show that endothelial
activation and systemic inﬂammation persist after iRBCs are
cleared from the circulation. This was most pronounced in CM,
where CRP remained raised 22-fold higher at 28-day follow-up
when compared with the HC group. However, signiﬁcant in-
ﬂammation and endothelial activation was also detectible in
UM, with CRP remaining 13-fold above that of the HC group
at 7-day follow-up and ICAM-1 and Ang2 remaining raised
until the 28-day follow-up. This persistence cannot be ex-
plained by the half-lives of these factors, because, for example,
CRP and Ang2 have half-lives of 19 hours [13] and 18 hours
[14], respectively.
Persistent endothelial activation was not speciﬁc to malaria.
In agreement with prior studies indicating persistent endotheli-
al activation after other common infections [15], there was also
endothelial activation in the group with mild nonmalarial in-
fections. Nonetheless, the long-term effect of malaria might be
anticipated to be particularly important in hyperendemic coun-
tries such as Malawi, where the frequency of repeated malaria
infections may be sufﬁcient to prevent return to baseline before
the next infection (malarial or otherwise). Thus children who
live in areas of high malaria transmission may be in a constant-
ly deregulated endothelial state. This may inﬂuence outcome
for patients in several different ways. First, subacute impair-
ment of endothelial barrier function, as indicated here by in-
creased Ang2, may increase invasion of bacteria or viruses into
the blood stream. This mechanism has been proposed to
explain the causal association between incidence of malaria and
bacteremia shown using epidemiological modeling in Kenya
[5]. Second, because endothelial activation is implicated in the
pathogenesis of a number of infections, including malaria and
bacterial sepsis, acquiring a subsequent infection while the en-
dothelium remains activated may have an endothelial priming
effect, increasing the vascular dysfunction and thus the severity
of disease. Speciﬁcally, because parasites that bind ICAM-1
have been shown to be associated with CM [12], the residual
ICAM-1 upregulation, indicated by raised sICAM-1 here, may
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select for parasite variants associated with higher incidence of
CM. Finally, in the long term, chronic endothelial activation
and inﬂammation may contribute to the endothelial changes
that cause cardiovascular disease [15, 16]. In industrialized
countries, the number of infectious episodes of common infec-
tions a person has accrued over their lifetime—their “pathogen
burden”—has been implicated in risk of myocardial infarction
in a dose–response fashion and is a better predictor of cardio-
vascular risk than any particular pathogen [15]. This indicates
that although each individual infection may only cause a small
residual insult to the vasculature, over multiple infectious
episodes this may accumulate to cause severe pathology. Given
the very high frequency of new malaria infections in many
parts of sub–Saharan Africa, malaria may contribute substan-
tially to this pathogen burden—even if the effect from each
infectious episode is small. Although there is a paucity of epide-
miological studies investigating the etiology of cardiovascular
diseases in sub–Saharan Africa, these diseases are a signiﬁcant
cause of morbidity and mortality [17]. As a higher proportion of
the population survives into and past middle age, their preva-
lence rates are likely to increase. Large epidemiological studies to
identify the speciﬁc risk factors in Africans are needed, and our
Table 1. Clinical Characteristics and Soluble Plasma Markers in Children With Cerebral Malaria, Uncomplicated Malaria, and Mild
Febrile Illness and in Healthy Controls
Characteristic
Healthy Controls
(n = 36)
Mild Febrile Illness
(n = 88)
Uncomplicated
Malaria (n = 84)
Cerebral Malaria
(n = 18)
Age, years, mean (95% CIa) 4.6 (3.7–5.7) 3.2 (2.8–3.6)* 4.7 (4.1–5.3) 4.1 (3.3–5.2)
Female sex, No. (%) 13 (36) 35 (40) 47 (56) 8 (44)
Clinical parameters on day 0, mean (95% CI)
Axillary temperature 36.6 (36.5–36.7) 38.4 (38.2–38.5)*** 38.5 (38.4–38.7)*** 39.0 (38.5–39.6)***
Heart rate, beats/minutes 109 (104–114) 127 (119–135)*** 130 (124–137)*** 145 (129–163)***
Systolic blood pressure, mmHg 107 (101–113) 114 (110–117)* 113 (110–117)* 97 (92–102)**
Respiratory rate, breaths/minutes 28 (26–30) 30 (29–31) 28 (27–29) 46 (42–51)***
Glucose, mmol/L 5.0 (4.8–5.2) 5.1 (4.9–5.3) 5.7 (5.4–6.0)** 5.6 (4.6–6.9)*
Lactate, mmol/L 1.8 (1.7–2.0) 1.7 (1.6–1.9) 2.3 (2.1–2.5) 5.2 (3.9–6.9)***
Hemoglobin, g/L 10.4 (9.9–11.0) 10.7 (10.3–11.1) 9.0 (8.6–9.4)** 6.1 (5.4–7.0)***
Platelets, ×109/L 380 (347–416) 300 (267–338)* 110 (93–131)*** 31 (21–46)***
Parasitemia, parasites ×103/µL 0 0 20 (9.9–40) 68 (27–171)
HIVb positive, No. (%) 0 (0) 4 (4.8) 3 (3.5) 2 (11.1)
sICAM-1, pg/mL day 0 198 (160–247) 316 (295–339)*** 464 (295–505)*** 624 (377–1033)***
sICAM-1, pg/mL day 7 (. . .) 258 (235–282) 343 (299–394)*** 478 (364–626)***
sICAM-1 ,pg/mL day 28 (. . .) 269 (242–299)* 277 (251–304)** 291 (201–421)
sE-selectin, pg/mL day 0 68 (57–82) 122 (105–142)*** 147 (130–160)*** 205 (158–266)***
sE-selectin, pg/mL day 7 (. . .) 76 (66–87) 79 (68–91) 109 (77–154)*
sE-selectin, pg/mL day 28 (. . .) 79 (68–92) 82 (74–91) 93 (64–135)
Ang2, pg/mL day 0 232 (207–261) 382 (339–431)*** 579 (523–641)*** 1536 (1190–1982)***
Ang2, pg/mL day 7 (. . .) 383 (333–440)*** 442 (389–502)*** 548 (401–749)***
Ang2, pg/mL day 28 (. . .) 311 (275–350)** 320 (285–359)** 307 (213–443)
sTM, pg/mL day 0 4.7 (4.2–5.2) 4.5 (4.2–4.9) 6.0 (5.4–6.5)* 9.1 (7.5–11.1)***
sTM, pg/mL day 7 (. . .) 4.7 (4.3–5.1) 5.0 (4.4–5.6) 5.6 (4.3–7.2)
sTM, pg/mL day 28 (. . .) 5.2 (4.8–5.6) 4.6 (4.1–5.3) 4.1 (3.4–5.1)
CRP, mg/mL enrollment 0.41 (.23–.74) 26.7 (20–35)*** 75 (61–92)*** 149 (111–199)***
CRP, mg/mL day 7 (. . .) 3.0 (2.0–4.4)*** 5.3 (4.2–6.7)*** 16.0 (8.3–32)***
CRP, mg/mL day 28 (. . .) 0.62 (.37–1.0) 0.73 (.48–1.1) 12.7 (3.1–52)***
F1 + 2 , pg/mL day 0 176 (140–220) 142 (120–167) 219 (180–268) 376 (245–577)*
F1 + 2 , pg/mL day 7 (. . .) 176 (135–229) 220 (186–260) 500 (279–898)***
F1 + 2 , pg/mL day 28 (. . .) 174 (138–221) 142 (111–182) 180 (105–310)
For each variable, differences between healthy controls and other patient groups were examined using a Fisher’s exact test (categorical variables) or 1-way analysis
of variance (continuous variables) with the Tukey honestly significant difference test to adjust for multiple comparisons. Comparisons were not made for
parasitemia or HIV. Abbreviations: Ang2, angiopoetin 2; CI, confidence interval; CRP, C-reactive protein; HIV, human immunodeficiency virus; sICAM-1, soluble
intercellular adhesion molecule 1; sTM, soluble thrombomodulin. *P < .05, **P < .01, ***P < .001.
a All mean values are geometric means and their 95% confidence intervals.
b HIV was tested for using rapid testing.
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data indicate that malaria should be considered within these
future studies.
There are several limitations to this study. First, loss to
follow-up of 50% of the patients in each of the groups may have
led to bias. Children with UM who attended follow-up had a
signiﬁcantly higher CRP on admission than those who did not
attend follow-up (followed-up: mean, 137 mg/mL, 95% conﬁ-
dence interval [CI], 107–166 mg/mL; not followed-up, mean =
71 mg/mL, 95% CI, 50–93 mg/mL; P≤ .01), which might indi-
cate that sicker patients were more likely to return to follow-up,
leading to an overestimation of the strength of difference with
the HC group. However, comparison of all clinical variables
Figure 1. Plasma markers at admission and at follow-up in Malawian children with malaria, nonmalarial febrile illness, and cerebral malaria compared
with healthy controls. Levels of soluble intercellular adhesion molecule 1, C-reactive protein, and angiopoetin 2 were measured by enzyme-linked immuno-
sorbent assay at admission and at 7 day and 28 day follow-up visits in 84 children with uncomplicated malaria, 88 children with nonmalarial febrile
illness, and 18 children with cerebral malaria. Results are compared with 36 Malawian healthy controls who were well children at the hospital for elective
surgical procedures. Horizontal lines indicate geometric means, and bars indicate 95% conﬁdence intervals. Numbers below data labels of the x-axis are
the number of children in each group at each time point. Comparison was performed with a 1-way analysis of variance with the Tukey honestly signiﬁcant
difference test to adjust for multiple comparisons. Asterisks (*) indicate a statistically signiﬁcant difference in comparison with the healthy controls:
*P≤ .05; **P≤ .01 ***P≤ .001. Abbreviations: Ang2, angiopoetin 2; CM, cerebral malaria; CRP, C-reactive protein; HC, healthy control; MF, nonmalarial
febrile illness; sICAM-1, soluble intercellular adhesion moleculre 1; UM, uncomplicated malaria.
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and all biomarkers among all patients who were followed-up
until 28 days with those who were lost to follow-up or excluded
did not indicate a systematic bias (data not shown). Second, al-
though the panel of plasma markers used are well validated as
indicators of endothelial activation [9], only Ang2 and E-selec-
tin are exclusively produced by the endothelium. In Indonesian
adults with malaria, high Ang2 levels predicted impaired endo-
thelial function, measured by endothelial-dependent vasodi-
latation [18]. In that population, these arterial tonometric
measurements improved to within normal range by 14 days. It
would be interesting to evaluate tonometry in African children
to examine whether the raised Ang2 levels at 28 days here are
associated with a persistently abnormal vasodilation response.
Third, because it was not possible to measure preinfection
levels of the biomarkers and we were not able to follow-up this
cohort long-term, we have not proven that malaria causes the
higher levels of biomarkers described at 28 day follow-up. It is
possible, although we think unlikely, that instead patients in the
febrile groups had preexisting higher baseline biomarker levels.
Finally, because we studied children with symptomatic disease
it remains unclear whether there is endothelial activation
induced by parasitemia that is not associated with febrile
illness, which would have important implications given the fre-
quency of asymptomatic malaria infections.
Further research is needed to clarify the extent and duration
of the endothelial perturbations described here and their rele-
vance in other malaria-prevalent countrie and to ascertain
whether burden of malaria infection is independently associ-
ated with adverse outcomes due to endothelial dysfunction in
the short or long term. If such studies conﬁrm a chronic effect
of repeated vascular insults by malaria infection, that would
have important implications: inﬂuencing the priority of pre-
venting malaria and indicating a need to target interventions
to older children and adults in addition to the young children
who die from acute illness. A further consideration is the use
of adjunctive therapies to prevent residual endothelial effects
in individuals with severe malaria or a high burden of infec-
tion. A candidate is statins, which have endothelial protective,
anti-inﬂammatory, and anticoagulant effects and prevent
cardiovascular disease even in those without hyperlipidemia
[16]. In malaria, statins reduce endothelial activation in vitro
and reduce neurodevelopmental sequelae after experimental
CM in mice [19]. Short courses of statins during acute illness
and convalescence could be targeted to individuals with
severe disease.
In conclusion, we demonstrate that in uncomplicated and
severe malaria signiﬁcant endothelial activation and inﬂamma-
tion persists for at least 1 month after elimination of iRBCs.
Given the huge burden of repeated infection with malaria, this
endothelial activation may represent a signiﬁcant and previous-
ly neglected contribution to long-term health that warrants
further evaluation for treatment and prevention strategies.
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